Skip to main content
BioCentury on BioBusiness
Feature Story

Afrezza, partnered

What Sanofi must do for Afrezza to recoup $1.5B raised from MannKind's investors

By Catherine Shaffer, Senior Writer

Having signed on as the commercial partner for MannKind Corp.'s Afrezza inhaled insulin, Sanofi is clearly betting it can succeed where Exubera inhaled insulin from Pfizer Inc. and Nektar Therapeutics failed. To make the numbers add up for its investors, the biotech has to hope the pharma is right.

Under last week's deal, Sanofi will pay $150 million up front and take over responsibility for global commercial, regulatory and development activities for Afrezza, which FDA approved in June to improve glycemic control in Type I and II diabetics. MannKind is eligible for up to $775 million in development, regulatory and sales milestones. The companies will split costs and profits, with Sanofi receiving 65% and MannKind 35%. Sanofi also agreed to advance up to $175 million at 8.5% interest to MannKind to cover its share of the collaboration's expenses.

Full Article

Taxing Innovation


    Navigating the new road in psychiatry

    The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling early drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia and depression, stakeholders will need to abandon traditional models, build on emerging genetic findings and capitalize on new capabilities in stem cell technology, imaging and computational modeling.


    Translational tidbits

    Astellas and Cancer Research UK team up to tackle autophagy in pancreatic cancer; the NIH bets big on bioelectronic therapeutics; a roundup of public-private partnerships.


    Liver, supercooled

    Harvard Medical School scientists have reported a method that triples the time rat livers can be preserved for transplant and could thus increase the number of donor organs available for patients. Spinout Organ Solutions is licensing the technology, and the company and the medical school plan to submit to the FDA next year.


    This Week in Therapeutics

    Inhibiting MFGE8 to prevent tumorigenic events promoting prostate cancer; DECTIN1 CAR-expressing T cells to treat opportunistic fungal infections; antibodies that stabilize SNCA to protect neurons in PD; and moree...


    This Week in Techniques

    EnPlex, a high throughput flow cytometry platform to assess potency and selectivity of small molecule enzyme inhibitors; Platypus, a reference genome-free algorithm that rapidly calls variants in clinical sequencing data; a two-gene signature that distinguishes between psoriasis and eczema; and more...

Subscribe Now
Free Trial